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Abstract 
Review on C12orf5, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: FR2BP, TIGAR 
HGNC (Hugo): C12orf5 
Location: 12p13.32 
DNA/RNA 
Description 
The human TIGAR gene is composed of 6 exons 
spanning genomic region about 50,4 kb (GenBank  
NC_000012.11). The transcript mRNA is 8,2 kb 
(GenBank NM_020375.2) and it is composed by 
the exon regions 5827..5937, 15914..15951, 
21673..21794, 34453..34530, 35901..36011 and 
36894..44662. 
Transcription 
The human TIGAR coding sequence consists of 
813 bp from the start codon to the stop codon. 
There are no splicing variants reported. 
Pseudogene 
A pseudogene of the ribosomal protein S15 has 
been located in the region 8981..9473 by 
computational analysis using a gene prediction 
method, but there is not experimental data proving 
it. 
 
Figure 1. Schematic representation of TIGAR location in chromosome 12, gene structure and transcript mRNA. Different 
numbering has been used considering chromosomal, gene or mRNA sequence. 
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Figure 2. Diagram of TIGAR structure from PDB (entry number: 3DCY). The PDF file does not contain information about the 
parts of the sequence that are not underlined. 
 
 
Protein 
Description 
Human TIGAR protein consists of 270 aminoacids, 
with a molecular weight of 30063 Da.  
It is composed of a bisphosphatase active site in 
which two histidines, His-11 and His-198, and one 
glutamic acid, Glu-102, are key residues for its 
function.  
TIGAR catalytic domain belongs to the histidine 
phosphatase superfamily of proteins, a conserved 
group of proteins which contain a domain with a 
histidine forming a phosphoenzyme transiently 
during the catalysis (Rigden, 2008). This domain 
shares similarity with enzymes of the 
phosphoglycerate mutase family (PGAM) and with 
the bisphosphatase domain of 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase (PFK-
2/FBPase-2), in which the three aminoacids in the 
catalytic domain are conserved. 
More information about TIGAR protein can be 
found in Uniprot Q9NQ88. 
Human TIGAR structure contains different motifs 
as represented in the image below (PDB reference 
3DCY). 
The crystallized structure of Danio rerio TIGAR is 
available in PDB (3E9D reference) and was 
published by Li and Jogl, 2009. 
Expression 
TIGAR mRNA is expressed in all the tissues in 
which it has been analysed and it is overexpressed 
in several cancer cell lines such as T-lymph Jurkat 
cancer, kidney HEK-293, liver HuH-7 and HepG2, 
lung A549, colon RKO, bone U2OS, brain GAMG, 
prostate LnCap, cervix HeLa and breast MCF7. 
All this information can be found in GeneCards 
(sections proteins and expression). 
Localisation 
TIGAR is mainly localized in the cytoplasm. Under 
hypoxic conditions, a relocalization of the protein 
linked to HK-2 (hexokinase 2) in the outer 
mitochondrial membrane has been described 
(Mathupala et al., 2009; Cheung et al., 2012). 
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Figure 3. Human TIGAR crystalized structure visualization 
in Jmol software. His-11 is represented in white, Glu-102 is 
in purple, His-198 is colored green and C and N terminus 
are represented in red and blue, respectively. A) General 
protein view. B) Zoom of the visualization to the catalytic 
core, with the two histidines represented and the phosphate 
group painted following the consensus-based coloring of 
atoms. C) Protein surface and inside-core representation. 
The central core of the protein is composed by a six-
stranded mixed β sheet flanked by α helices on both sides. 
Function 
TIGAR was identified by microarray analysis of 
gene expression after TP53 induction (Bensaad et 
al., 2006). TIGAR plays a role in the TP53 tumor 
suppressor program by reducing reactive oxygen 
species (ROS) levels and preventing DNA damage-
induced apoptosis. Their functions are based on 
glycolysis inhibition and the enhancement of 
pentose phosphate pathway (PPP). 
TIGAR is a bisphosphatase that hydrolyzes 
Fructose-2,6-bisphosphate to Fructose-6-phosphate, 
which can enter the PPP to generate NADPH and 
ribose-5-phosphate, thus, reducing oxidative stress 
and generating nucleotide precursors (Bensaad et 
al., 2006). 
Beta-D-fructose 2,6-bisphosphate + H2O ⇔ D-
fructose 6-phosphate + phosphate 
The switch from TP53-induced cell-cycle arrest to 
apoptosis following maintained stress is associated 
with downregulation of TIGAR and therefore the 
loss of P53-dependent survival agents could be the 
cause of the apoptotic response. It has been 
proposed that TP53-dependent metabolism 
regulation could be orchestrated by different 
mechanisms other than the ones that regulate TP53-
induced apoptosis. TIGAR antiapoptotic effects are 
oxidative-stress dependent. The apoptosis induction 
by other mechanisms is not affected by TIGAR, as 
it was shown in IL-3-dependent apoptosis FL5.12 
cell line, and in anti-Fas induced apoptosis in U2OS 
cells, suggesting that TIGAR can modulate 
apoptosis in a cell-dependent manner (Bensaad et 
al., 2006). 
As described previously, under hypoxic conditions 
TIGAR is localized in outer mitochondrial 
membrane. In this situation, it binds together with 
HK2 to mitochondria (Mathupala et al., 2009) in a 
HIF1α (hypoxia-inducible factor 1α) dependent 
manner, and limits ROS levels.  
If HK2 is not present, oxidative stress reduction by 
TIGAR is lower. It has been shown that mutant 
TIGAR TM (Triple Mutant without enzymatic 
activity: H11A/E102A/H198A) is able to relocalize 
to mitochondria in response to hypoxia and, indeed, 
is able to bind to HK2 in the outer mitochondrial 
membrane.  
Therefore, the maintenance of mitochondrial 
membrane potential by TIGAR is independent of its 
bisphoshatase activity. However, the single deletion 
of four aminoacids in the C-terminus (258-261) 
avoided TIGAR mobilization to the mitochondria 
after hypoxia, although its bisphosphatase activity 
remained unaltered.  
The double mutant TM TIGAR/258-261 was not 
able to reduce ROS levels (Bensaad et al., 2006; 
Cheung et al., 2012). In conclusion, TIGAR lowers 
ROS levels both by inhibiting glycolysis and by 
enhancing an adequate mitochondrial function 
coupling to HK2. 
TIGAR effects have also been related to autophagy 
as an inhibition of this cell process was described 
when cells were exposed to stress conditions such 
as nutrient starvation or metabolic stress, in parallel 
with an overexpression of TIGAR and a decrease in 
ROS cell levels. After TIGAR suppression, 
autophagy was induced to moderate apoptotic 
response by restraining ROS levels (Bensaad et al., 
2009). 
The relation between autophagy and apoptosis can 
be modulated differently depending on the stimulus 
and cell type.  
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Figure 4. Schematic representation of TIGAR in metabolic pathways. The main enzymes involved in glycolysis are shown, as 
well as the substrates and products of TIGAR activity. The pentose phosphate pathway and mitochondrial metabolic pathways 
have been summarized. HK: hexokinase, PGI: phosphoglucose isomerase, PFKFB3: phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 3, PFK-1: phosphofructokinase-1, DHAP: dihydroxyacetone phosphate, GA-3-P: glyceraldehyde 3-phosphate, 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase, 1,3-BPG: 1,3-bisphosphoglycerate, mTORC1: mammalian target of 
rapamycin complex 1, PEP: phoshoenolpyruvate, GSH: glutathione. 
 
 
D-galactose (D-gal) treatment of neuroblastoma 
cells induced necroptosis and autophagy, as shown 
by upregulation of Bmf, Bnip3, Atg5 and TIGAR, 
but there were no changes in expression in genes 
related to apoptosis (Li et al., 2011). 
Recently, it has been described a decrease in 
steady-state mRNA levels of TIGAR when the 
human hepatocellular carcinoma HepG2 cell line 
was exposed to high oxidative stress conditions 
induced by the superoxide radical-generating 
menadione, hydrogen peroxide (H2O2) or nutrient 
starvation, in parallel with a down-regulation of the 
damage-regulated autophagy modulator (DRAM). 
mRNA levels of both genes were recovered when 
cells were treated with antioxidants such as GSH or 
N-acetylcysteine, suggesting a complex regulation 
of tumor suppressor genes by ROS levels (Kim et 
al., 2013). In front of a disruption in the 
homeostasis balance of the cell, TIGAR would 
provide cytoprotection by its antioxidant properties 
rather than its ability to inhibit autophagy. After a 
threatening stimulus, a rapid increase in the 
autophagic flux occurs mostly regulated by post-
translational modifications, followed by a 
transcriptionally-mediated delayed autophagyc 
response phase, in which TP53 would be activated. 
In this context, TIGAR would be rapidly 
transactivated and would mediate its antioxidant 
response, while autophagy is enhanced by other 
transcriptionally activated targets, such as DRAM 
(Pietrocola et al., 2013). Some authors have 
proposed a TP53-orchestrated mechanism by which 
this protein would regulate stress-induced 
autophagy by balancing two proteins with opposite 
effects: TIGAR and DRAM (Dewaele et al., 2010; 
Zhang et al., 2010). 
In TP53 knock-out mice (TP53-/-) cardioprotection 
against ischemic injury and resistance to cardiac 
remodeling were observed, and a significant 
TIGAR overexpression was described. The TIGAR 
knock-out (TIGAR-/-) had the same effects and a 
TP53-dependent mechanism of autophagy 
inhibition through the mitophagy enhancer Bnip3 
was described. Double knock-out of TP53 and 
TIGAR mice exposed to ischemia responded with 
an increase in ROS levels, followed by an 
overexpression of Bnip3 that lead to mitophagy 
and, thus, cardioprotection. The activation of Bnip3 
and mitophagy was recovered by NAC, confirming 
that TIGAR-mediated mitophagy inhibition is 
mediated by ROS. Ventricular remodeling after 
myocardial infarction is a consequence of both 
impaired mitochondrial integrity and enhanced 
apoptosis, whereas mitophagy helps cells to 
undergo mitochondrial damage and avoid 
apoptosis, resulting in a diminished initial infarct 
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size, less ventricular remodeling and restored 
homeostasis in ischemic myocardium (Kimata et 
al., 2010; Hoshino et al., 2012). 
The analysis of lung tissues from idiopathic 
pulmonary fibrosis patients revealed decreased 
autophagyc activity, evidenced by less LC3 and p62 
expression. When these cells were treated with 
TGFβ in vitro, impairment in autophagy was 
observed, in parallel with an increase in TIGAR 
expression, although the possible mechanism 
connecting TGFβ and TIGAR was not described 
(Patel et al., 2012). 
In a co-culture system, Martinez-Outschoorn et al. 
showed that oxidative stress-induced autophagy 
correlated with Cav-1 downregulation in cancer 
associated fibroblasts, and with overexpression of 
TIGAR in adjacent cancer cells. Consequently, 
autophagy cancer associated fibroblasts provide 
recycled nutrients for cancer cell metabolism and, 
moreover, prevent cancer cells death by 
upregulating TIGAR and thus conferring resistance 
to apoptosis and autophagy (Martinez-Outschoorn 
et al., 2010).  
Further studies by the same group demonstrated 
that the metabolic coupling between cancer cells 
and fibroblasts can explain tamoxifen resistance as 
cancer associated fibroblasts enhance the activity of 
TIGAR in cancer cells, providing protection against 
tamoxifen-induced apoptosis, which was much 
higher in monocultures of cancer cells alone 
(Martinez-Outschoorn et al., 2011). In another 
study, glutamine was described as a needed factor 
for Cav-1 downregulation in cancer associated 
fibroblasts and for the decrease in autophagy 
mediators and markers in cancer cells, establishing 
a model in which autophagy fibroblasts may serve 
as a source of glutamine to fuel cancer cell 
mitochondrial activity. Therefore, a cycle between 
catabolic tumor stroma cells and anabolic tumor 
cells has been proposed to explain the relations 
between cells in tumor environment (Ko et al., 
2011). 
Besides, TIGAR has also been proposed to be an 
anticancer therapy target gene considering that 
autophagy inhibition in cancer cells would probably 
increase cell death (Dodson et al., 2013). 
All these studies confirm that TIGAR functions are 
not only restricted to glycolysis regulation, as this 
protein plays key roles in different cell processes 
involving oxidative stress restriction. 
Activation and regulation 
TIGAR belongs to that group of TP53 target genes 
that become rapidly activated by low levels of 
stress. There are two possible TP53 binding sites in 
TIGAR gene: one upstream of the first exon (BS1) 
and one within the 1st intron (BS2), which is the 
most efficient one and has been validated by 
chromatin immunoprecipitation (ChIP) analysis 
(Bensaad et al., 2006). 
In an experimental approach, TIGAR was induced 
by Actinomycin D and Adriamycin (Bensaad et al., 
2006), two well-known activators of TP53, and also 
by Nutlin-3a, an antagonist of Mdm2 (Hasegawa et 
al., 2009). Other stimuli that have been described to 
trigger TIGAR expression are radiotherapy (Peña-
Rico et al., 2011), glutamine (Ko et al., 2011), 
chemotherapy (Madan et al., 2012), UV light 
(Madan et al., 2012), TNFα and radiotherapy 
mimetics (Sinha et al., 2013). 
When DNA damage occurs, TP53 is expressed 
either to repair DNA or lead the cell towards 
apoptosis. High ROS levels can compromise DNA 
stability which, in turn, could help cells to 
accumulate mutations and become tumorigenic. As 
TIGAR reduces ROS levels, it has been proposed 
as a tumor suppressor gene, although it should be 
taken into account that, as TIGAR can help tumor 
cells survival, it could act as an oncogene in some 
situations. TP53 is able to suppress tumor 
development when mechanisms of apoptosis, 
senescence and cell-cycle arrest are impeded. This 
supports the idea that metabolism, and thereby 
TIGAR, has a key role in cancer development (Li et 
al., 2012; Valente et al., 2013). 
TIGAR expression can also be modulated in a TP53 
independent manner, as results from studies with 
the TP53 null T98G and H1299 cell lines suggest 
(Bensaad et al., 2006; Peña-Rico et al., 2011). The 
mechanisms implicated in the regulation of TIGAR 
expression in the absence of TP53 are unclear. The 
CRE-binding protein (CREB) has been described to 
regulate TIGAR expression through a CRE-binding 
site at the TIGAR promoter, which was first 
annotated by bioinformatic analysis and then 
confirmed by electrophoretic mobility shift assay 
(EMSA) and ChIP. CREB knockdown reduced 
enhanced promoter activity and TIGAR expression; 
whereas CREB overexpression resulted in 
enhanced promoter activity and TIGAR expression 
levels (Zou et al., 2013).  
Another transcription factor, SP1, was found to 
bind to TIGAR promoter in a SP1-binding site 
located in a very short region (-56/-4) both in vitro 
and in vivo, and was considered a key factor for 
proper basal activity of TIGAR promoter (Zou et 
al., 2012).  
Recently, some authors have identified HIF-1α as a 
potential regulator of SCO2 and TIGAR gene 
expression suggesting the involvement of 
P300/CBP-associated factor (PCAF) in differential 
recruitment of HIF-1α and p53 to the promoter of 
TIGAR and/or SCO2 genes in response of hypoxia 
in tumoral cells (Rajendran et al., 2013). 
Chromosomal rearrangements: copy number 
variants 
Some alterations affecting TIGAR genome region 
have been described in patients, some of them 
showed phenotypic effects.  
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Gain of 12:189578-34178209 resulted in 
hydronephrosis, micrognathia, edema, depressed 
nasal bridge, tricuspid regurgitation and 
diaphragmatic eventration.  
Patients with gain of 12:189561-41878937 suffered 
global developmental delay.  
The ones with gain of 12:230361-20643702 showed 
intellectual disability and electroencephalogram 
with localized low amplitude activity, whereas gain 
of 12:191619-8327369 resulted in macroencephaly, 
visual impairment, intellectual disability, muscular  
 
hipotonia, and seizures. For more information, see 
DECIPHER. 
Homology 
Location in the mouse: chromosome 6, 61.92 cM, 
127085116-127109550 bp, complement strand 
(MGI). For a comparison of the gene among Homo 
sapiens, mouse, rat, chimpanzee, cattle, rhesus 
macaque, dog, chicken and zebrafish see MGI. 
For all species known gene tree, see: Treefam 
database. 
 
Figure 5. Orthologs (adapted from BLAST Local Alignment Tool). 
 
 
 
Figure 6. Histogram of mutations found among the aminoacid sequence of TIGAR protein. The maximum number of 
substitutions at any specific genomic region is represented in Y axis. R90G is the most common aminoacid substitution, caused 
by 5 different genomic mutations. Histidine phosphatase family homolog domain is represented in green and copy number 
variants are represented in blue (gain of function) and red (loss of function). Adapted from: COSMIC Database. 
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Mutations 
Note 
There have been observed 22 somatic mutations in 
patient tumor samples collected in the COSMIC 
database. 
Nonsense substitutions: 1, located in c.466G>T 
(p.G156*). 
Missense substitutions: 16, which represent 82% of 
the mutations described among all patients. Only 
two missense substitutions have been found in more 
than one patient: c.268A>G (p.R90G) was found in 
5 patients and c.215G>T (p.R72I) was found in 2 
patients. 
Synonymous substitutions: 4. 
No deletions, insertions or chromosomal fusions in 
TIGAR gene have been described in any tumor 
sample. 
Genomic variants 
There are 878 SNP variants described but none of 
them have clinical significance described 
(GeneCards). 
Implicated in 
Various cancers 
Prognosis 
Despite that little is known about the implication of 
TIGAR in cancer, there are some authors that point 
out about the importance of p53 targets such as 
cytochrome c oxidase 2 (SCO2) or TIGAR in the 
prognosis of breast cancer patients. Some studies 
indicated that p53, the most commonly mutated 
tumor suppressor gene, may have important 
functions in the regulation of energy-generating 
metabolic pathways that switch from oxidative 
phosphorylation to glycolysis via the synthesis of 
SCO2 and TIGAR (Won et al., 2012). 
Oncogenesis 
The p53 tumor suppressor pathway coordinates 
DNA repair, cell-cycle arrest, apoptosis, and 
senescence to preserve genomic stability and 
prevent tumor formation. TIGAR has been 
identified as a p53-inducible gene. TIGAR 
expression lowers fructose-2,6-bisphosphate levels 
in cells, resulting in an inhibition of glycolysis and 
an overall decrease in ROS levels. These functions 
of TIGAR correlate with an ability to protect cells 
from ROS-associated apoptosis, and consequently, 
knockdown of endogenous TIGAR expression 
sensitizes cells to p53-induced death. Expression of 
TIGAR may therefore modulate the apoptotic 
response to p53, allowing survival in the face of 
mild or transient stress signals that may be reversed 
or repaired. The decrease of intracellular ROS 
levels in response to TIGAR may also play a role in 
the ability of p53 to protect from the accumulation 
of genomic damage (Bensaad et al., 2006). In an in 
vitro model of nasopharyngeal cancer, 1-(3-C-
ethynyl-beta-d-ribo-pentofuranosyl) cytosine 
(ECyd), a RNA-nucleoside anti-metabolite with 
potent anticancer activity, acts by downregulating 
TIGAR and depleting NADPH. The overexpression 
of TIGAR was able to rescue cells from ECyd-
induced growth inhibition, demonstrating a novel 
mechanistic action of ECyd on TIGAR. This study 
suggests a novel link between RNA metabolism 
and TIGAR regulation (Lui et al., 2010). In human 
cervical carcinoma cells, RNAi-mediated citrate 
synthase knockdown accelerated cancer cell 
metastasis and proliferation being these effects 
related to deregulation of the p53/TIGAR and 
SCO2 pathways (Lin et al., 2012). In other studies, 
TIGAR also mediates de-phosphorylation of RB 
(retinoblastoma) and stabilisation of RB-E2F1 
complex thus delaying the entry of cells in S phase 
of the cell cycle. Thus, TIGAR inhibits 
proliferation of cancer cells and increases drug-
mediated tumour regression by promoting p53-
mediated cell-cycle arrest (Madan et al., 2011; 
Madan et al., 2012). 
Hepatic cancer 
Note 
Silencing TIGAR by RNAi induces apoptotic and 
autophagy cell death in HepG2 cells, and this data 
raise hope for the future successful application of 
TIGAR siRNA in patients with hepatocellular 
carcinoma (HCC) (Ye et al., 2013). 
Breast cancer 
Note 
In a model of MCF7 breast cancer cells co-cultured 
with non-transformed fibroblasts, glutamine 
protects MCF7 cells against apoptosis, via the 
upregulation of the anti-apoptotic and anti-
autophagic protein TIGAR (Martinez-Outschoorn 
et al., 2011). The authors showed that glutamine 
cooperates with stromal fibroblasts to confer 
tamoxifen-resistance in MCF7 cancer cells (Ko et 
al., 2011). Moreover, Won et al. (2012) have 
analysed the expression of p53, SCO2, TIGAR, and 
COX in 113 cases of invasive breast cancer using 
immunohistochemistry. A high expression of p53, 
SCO2, TIGAR, and COX was noted in 27,5% (31 
cases), 84,1% (95 cases), 74,3% (84 cases), and 
73,4% (83 cases) of the breast tumors, respectively. 
A high p53 expression was significantly associated 
with low expression levels of SCO2 (P = .008), 
COX (P < .0001), and TIGAR (P = .007). These 
results suggest that p53 can modulate the metabolic 
pathways via the proteins SCO2 and TIGAR in 
human breast cancer. TIGAR and p53 can lower the 
cellular sensitivity to ROS-associated apoptosis, 
and this potentially contributes to the survival of 
cells undergoing mild, reversible stress by different 
anti-tumoral drugs (Won et al., 2012). 
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Head and neck cancer 
Note 
In a nasopharyngeal cancer, the onco-protein kinase 
c-Met maintains TIGAR expression. Inhibition of 
c-Met resulted in significant downregulation of 
TIGAR and subsequent depletion of intracellular 
NADPH. The results provide the first evidence 
linking c-Met, TIGAR and NADPH regulation in 
human cancer cells suggesting that inhibition of a 
tyrosine kinase/TIGAR/NADPH cascade may have 
therapeutic applicability in human cancers (Lui et 
al., 2011). 
Lung cancer 
Note 
Sinthupibulyakit et al. (2010) have shown that a 
glycolytic inhibitor, 2-deoxy-D-glucose (2DG), 
exhibits a cytotoxic effect on non-small cell lung 
cancer in a p53-dependent manner. 2DG 
significantly inhibits ATP production in p53-
deficient lung cancer cells (H358) but not in p53-wt 
cells (A549). This effect is explained by the ROS 
increase from OXPHOS that induces the expression 
of p53 antioxidants targets such as cytochrome c 
oxidase 2 (SCO2) and TIGAR. Therefore, killing of 
cancer cells by this inhibitor of glycolysis is more 
efficient in cancer cells without functional p53 that 
protects against metabolic stress by up-regulation of 
TIGAR (Sinthupibulyakit et al., 2010).  
Other authors point out the importance of 
autophagy as a cellular homeostatic process to 
determine cell fate decisions under conditions of 
stress. Deregulation of autophagy impacts 
numerous human diseases including cancer and 
chronic lung diseases. TIGAR could be implicated 
in the impairment of autophagy by TGF-β(1) and 
may represent a mechanism for the promotion of 
fibrogenesis in idiopathic pulmonary fibrosis (Patel 
et al., 2012). 
Intestinal cancer and ulcerative 
colitis 
Note 
The ability of TIGAR to contribute to the growth 
and survival of cells in rapidly proliferating tissue 
suggested a possible contribution of TIGAR to the 
development or progression of malignancies. In a 
mouse model of intestinal tumor induced by 
deletion of APC in the intestinal stem cells, TIGAR 
expression was increased and a reduction in tumor 
development and an enhancement of survival in 
TIGAR-/- mice were described. Furthermore, using 
an in vitro organoid culture model, impaired growth 
of TIGAR-/- cells derived from the crypt of the 
small intestine was rescued by supplementation 
with nucleosides and the antioxidant N-acetyl 
cysteine In the other hand, in a mouse model of 
ulcerative colitis TIGAR plays an important role in 
tissue regeneration and that lack of TIGAR results 
in a failure to repair damaged intestinal epithelium. 
TIGAR is overexpressed in crypts during the 
recovery of proliferation in WT mice. The lack of 
TIGAR results in a failure to repair damaged 
intestinal epithelium and increase in oxidative 
damage. In these systems, therefore, TIGAR 
expression is necessary to maintain normal healthy 
tissues following stress or damage. Therefore, while 
loss of TIGAR is deleterious to the recovery from 
intestinal damage, lack of TIGAR becomes 
advantageous under conditions where enhanced 
proliferation occurs in the context of tumor 
development and progression of malignancies. In 
conclusion, TIGAR is not required for normal 
tissue growth and development but becomes 
important in supporting rapid proliferation in adult 
intestinal epithelium (Cheung et al., 2013). 
Multiple myeloma 
Note 
Multiple myeloma cells present problems in the 
expression of oncoprotein MUC1-C. The inhibition 
of MUC1-C increases ROS and is also associated 
with down-regulation of TIGAR, resulting in the 
decrease in NADPH and glutathione (GSH) levels. 
The suppression of TIGAR and NADPH levels 
contributes to ROS-mediated apoptosis/necrosis of 
multiple myeloma cells. These findings indicate 
that multiple myeloma cells are dependent on 
MUC1-C and TIGAR for maintenance of redox 
balance and that targeting MUC1-C activates a 
cascade involving TIGAR suppression that 
contributes to multiple myeloma cell death (Yin et 
al., 2012). 
Chronic lymphocytic leukemia 
Note 
In chronic lymphocytic leukemia a correlation 
between sensitivity to fludarabine and TIGAR 
induction mediated by p53 was described. The 
sensitivity of fludarabine was variable despite all 
patients analysed had wild type p53 (López-Guerra 
et al., 2008). 
Cervix carcinoma 
Note 
In human cervical carcinoma cells, RNAi-mediated 
citrate synthase inhibition accelerated cancer cell 
proliferation and metastasis in in vitro assays and in 
vivo tumor xenograft models. The main effects of 
this knockdown are related with severe defects in 
respiratory activity and marked decreases in ATP 
production, but increases in glycolytic metabolism, 
resulted from deregulation of the p53/TIGAR and 
SCO2 pathways. This phenotypic change was 
completely reversed by p53 reactivation suggesting 
the implication of TIGAR in this malignant 
proliferation (Lin et al., 2012). 
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Glioblastoma 
Note 
Wanka et al. (2012) have shown in glioblastoma 
that TIGAR is overexpressed and its expression 
reduces cell death induced by glucose and oxygen 
restriction. Metabolic analyses reveal that TIGAR 
inhibits glycolysis and promotes respiration. 
Further, generation of ROS is reduced whereas 
levels of reduced GSH are elevated in TIGAR-
expressing cells (Wanka et al., 2012). These results 
agree with the potential of TIGAR as an 
antitumoral target demonstrated by Peña-Rico et al. 
(2011), who analysed the effects of TIGAR 
knockdown in U87MG and T98G glioblastoma-
derived cell lines and concluded that TIGAR 
abrogation provides a novel adjunctive therapeutic 
strategy against glial tumors by increasing 
radiation-induced cell impairment, thus allowing 
the use of lower radiotherapeutic doses. Gliomas 
are resistant to radiation therapy, as well as to 
TNFα induced killing. Radiation-induced TNFα 
triggers Nuclear Factor κB (NFκB)-mediated 
radioresistance. The existence of ATM-NFκB axis 
that regulates the metabolic modulator TIGAR 
suggests its implication in the mechanisms through 
which inflammation could affect resistance and 
adaptation to radiomimetics despite concurrent 
induction of death (Sinha et al., 2013).  
Recently, in a neuroblastoma SH-SY5Y cell model 
a novedous sonodynamic therapy has been assayed. 
This noninvasive modality for cancer treatment is 
based on the selective activation of a sonosensitizer 
agent by acoustic cavitation. The activated 
sonosensitizer agent might generate reactive oxygen 
species leading to cancer cell death. This therapy 
showed a significant decrease in SH-SY5Y cell 
proliferation in vitro in two and three-dimensional 
neuroblastoma models and this effect was 
accompanied by a significant decrease in the 
TIGAR mRNA expression 24 hours after 
sonodynamic treatment (Canaparo et al., 2013). 
Alzheimer's disease and 
neurodegeneration 
Note 
Some authors reported that TIGAR protein levels 
were decreased in various stages of Alzheimer's 
disease dementia severity, suggesting diminishing 
effect of ATM-p53 signalling in counteracting cell 
death induced by glycolysis/OXPHOS. The 
progressive decrease of TIGAR expression reported 
agrees with the findings of altered post-translational 
modification of TP53, which result in increased 
formation of functionally inactive TP53 monomers 
and dimers, but not functionally active TP53 
tetramers in Alzheimer's disease patients' brains (Di 
Domenico et al., 2009; Katsel et al., 2013). 
Moreover, the reported elevated expression of 
conformationally altered unfolded TP53 in 
peripheral blood cells from patients with 
Alzheimer's disease (Uberti et al., 2008) raises the 
question of the impact of protein structural changes 
on the TP53 activity during progression of 
dementia. TP53 activates TIGAR under low levels 
of stress. However, following extended exposure to 
stress and the induction of the TP53-mediated 
apoptotic response, TIGAR expression is reduced, 
suggesting that the induction of the apoptotic 
response may reflect the loss of protection by the 
TP53-inducible survival signals (Bensaad et al., 
2006). Therefore, TIGAR may play a critical role in 
the switch of TP53-induced responses to stress and 
a decrease in its expression may have negative 
consequences for the survival of cells during 
progression of dementia (Madan et al., 2012). 
Diabetes and obesity 
Note 
Studies performed in rats with diabetes mellitus to 
evaluate the potential role of p53 and its 
transcriptional targets in exercise-induced 
mitochondrial adaptation in skeletal muscle showed 
a decrease in p53 and TIGAR protein levels, 
indicating that exercise training can attenuate 
oxidative stress and increase mitochondrial DNA 
content in skeletal muscle. Agreeing with these 
results, suppression of p53 and TIGAR expression 
could play a role in preventing oxidative stress in 
insulin resistance (Qi et al., 2011).  
In the same direction Derdak et al. (2011) reported 
that susceptibility to ethanol-induced liver damage 
in different rat strains and the promotion of insulin 
resistance is correlated with p53 activation and the 
activation of TIGAR. 
To be noted 
Conclusion: In summary, since TIGAR was 
discovered in 2006 as a p53 target activated in 
response to moderated stress, several functions 
related to its fructose2,6-bisphosphatase activity 
have been described. TIGAR has become a key 
protein in the regulation of cell processes such as 
apoptosis, autophagy, DNA repair and control of 
oxidative stress, determining the fate of the cell in 
response to different insults. The role of TIGAR in 
maintaining tumor cell survival is highlighted by 
the fact that some tumor types have elevated levels 
of TIGAR expression (Wanka et al., 2012; Won et 
al., 2012) and the inhibition of different therapeutic 
targets is associated with a decrease of TIGAR 
expression. TIGAR can helps to support 
tumorigenesis by limiting ROS and providing 
precursors for nucleotide synthesis. These data 
predict that inhibition of TIGAR may carry 
therapeutic advantage in cancer treatments as 
demonstrated in different cancer models (Peña et 
C12orf5 (chromosome 12 open reading frame 5) Simon H, et al. 
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al., 2011; Martinez-Outschoorn et al., 2011; 
Cheung et al., 2013). 
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